What is CARsgen Therapeutics Holdings Current Ratio?
CARsgen Therapeutics HoldingsCRTHF 24 Current Ratio is 5.73 as of Dec. 2025, which is 21% below its 10-year median of 7.27. GuruFocus rates CRTHF with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 1,408 Biotechnology companies, CARsgen Therapeutics Holdings ranks better than 62% on this metric.
CARsgen Therapeutics Holdings has a current ratio of 5.73. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for CARsgen Therapeutics Holdings's Current Ratio or its related term are showing as below:
CRTHF'
s Current Ratio Range Over the Past 10 Years
Min: 0.11 Med: 7.27 Max: 13.45
Current: 5.73
During the past 7 years, CARsgen Therapeutics Holdings's highest Current Ratio was 13.45. The lowest was 0.11. And the median was 7.27.
CRTHF's Current Ratio is ranked better than 62% of 1408
companies
in the Biotechnology industry
Industry Median: 3.9
vs CRTHF: 5.73
CARsgen Therapeutics Holdings (OTCPK:CRTHF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
CARsgen Therapeutics Holdings Current Ratio Related Terms
CARsgen Therapeutics Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRTHF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, CARsgen Therapeutics Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CARsgen Therapeutics Holdings Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where CARsgen Therapeutics Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARsgen Therapeutics Holdings (CRTHF) has a Current Ratio of 5.73 as of Dec. 2025. This is 21% below median its historical median of 7.27. Over the past decade, CARsgen Therapeutics Holdings' Current Ratio has ranged from 0.11 to 13.45. According to the industry distribution chart, CARsgen Therapeutics Holdings ranks #535 out of 1408 companies in the Biotechnology industry, placing it in the top 38%.
Is CARsgen Therapeutics Holdings' Current Ratio too high?
CARsgen Therapeutics Holdings' current Current Ratio of 5.73 is 21% below median its 10-year median of 7.27. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 13.45. The Biotechnology industry median Current Ratio is 3.90. CARsgen Therapeutics Holdings' value of 5.73 is 46.9% above this industry median. Based on the distribution chart, CARsgen Therapeutics Holdings ranks #535 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CARsgen Therapeutics Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does CARsgen Therapeutics Holdings' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CARsgen Therapeutics Holdings ranks #535 out of 1408 companies for Current Ratio. This puts CARsgen Therapeutics Holdings in the upper half of its industry. The industry median Current Ratio is 3.90. CARsgen Therapeutics Holdings' value of 5.73 is 46.9% above this benchmark. Historically, CARsgen Therapeutics Holdings' own Current Ratio has ranged from 0.11 to 13.45 over the past decade. While the company's 10-year median is 7.27 vs. the industry median of 3.90, CARsgen Therapeutics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CARsgen Therapeutics Holdings's current Current Ratio of 5.73 is 46.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CARsgen Therapeutics Holdings's current Current Ratio is 5.73, which is 21% below median its own 10-year median of 7.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARsgen Therapeutics Holdings stock overvalued right now?
CARsgen Therapeutics Holdings (CRTHF) has a current Current Ratio of 5.73. The current Current Ratio is 5.73, which is 21% below median its 10-year median of 7.27 and 46.9% above the Biotechnology industry median of 3.90. CARsgen Therapeutics Holdings' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For CARsgen Therapeutics Holdings (CRTHF), the current Current Ratio is 5.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CARsgen Therapeutics Holdings Business Description
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America. During the year, a majority of the Group's revenue was derived from one customer located in the Chinese mainland.
24GF Score
Get the complete analysis for CRTHF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRTHF has been successfully added to your 
